Trial reportBMJ open2020
Effect of medicines management versus standard care on readmissions in multimorbid patients: a randomised controlled trial.
Trial report in BMJ open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02336113 (Oslo Pharmacist Intervention Study - Effect on Readmissions), which is not on this map. Cited by 19 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Oslo Pharmacist Intervention Study - Effect on Readmissions
Who cites it
19 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Transitional Care Interventions From Hospital to Community to Reduce Health Care Use and Improve Patient Outcomes: A Systematic Review and Network Meta-Analysis.JAMA network open · 2023Pooled it
- Medication review in hospitalised patients to reduce morbidity and mortality.The Cochrane database of systematic reviews · 2023Pooled it
- Clinical, economic and humanistic outcomes of medication therapy management services: A systematic review and meta-analysis.Frontiers in pharmacology · 2023Pooled it
- Effect of integrated medicines management on quality of discharge medication information-a secondary endpoint in a randomized controlled trial.International journal for quality in health care : journal of the International Society for Quality in Health Care · 2024Trial
- Health-related quality of life among older adults following acute hospitalization: longitudinal analysis of a randomized controlled trial.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024Trial
- Interdisciplinary collaboration across secondary and primary care to improve medication safety in the elderly (The IMMENSE study) - a randomized controlled trial.BMC health services research · 2022Trial
- Trial
- Potentially inappropriate prescriptions in acutely admitted older patients: a development study to create a clinical decision support tool using a Delphi process.European geriatric medicine · 2026Article
- Design and evaluation of a comprehensive training program for hospital-based clinical pharmacists - various, active, and work-integrated learning.Exploratory research in clinical and social pharmacy · 2025Article
- Facilitators and barriers to medication self-management for patients with multiple long-term conditions transitioning from hospital to home.Exploratory research in clinical and social pharmacy · 2025Article
- Multimorbidity Management: A Scoping Review of Interventions and Health Outcomes.International journal of environmental research and public health · 2025Article
- Implementation of hospital-initiated complex interventions for adult people with multiple long-term conditions: a scoping review.BMC health services research · 2025Article
- Investigating the impact of a pharmacist intervention on inappropriate prescribing practices at hospital admission and discharge in older patients: a secondary outcome analysis from a randomized controlled trial.Therapeutic advances in drug safety · 2024Article
- Effectiveness of pharmacist-led medication reconciliation on medication errors at hospital discharge and healthcare utilization in the next 30 days: a pragmatic clinical trial.Frontiers in pharmacology · 2024Article
- 'The way you talk, do I have a choice?' Patient narratives of medication decision-making during hospitalization.International journal of qualitative studies on health and well-being · 2023Article
- A Trial-Based Cost-Utility Analysis of a Medication Optimization Intervention Versus Standard Care in Older Adults.Drugs & aging · 2023Article
- Clinical pharmacist intervention to improve medication safety for hip fracture patients through secondary and primary care settings: a nonrandomised controlled trial.Journal of orthopaedic surgery and research · 2023Article
- Recommendations for wider adoption of clinical pharmacy in Central and Eastern Europe in order to optimise pharmacotherapy and improve patient outcomes.Frontiers in pharmacology · 2023Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the effect of pharmacist-led medicines management in multimorbid, hospitalised patients on long-term hospital readmissions and survival.
designParallel-group, randomised controlled trial.
settingRecruitment from an internal medicine hospital ward in Oslo, Norway. Patients were enrolled consecutively from August 2014 to the predetermined target number of 400 patients. The last participant was enrolled March 2016. Follow-up until 31 December 2017, that is, 21-40 months.
participantsAcutely admitted multimorbid patients ≥18 years, using minimum four regular drugs from minimum two therapeutic classes. 399 patients were randomly assigned, 1:1, to the intervention or control group. After excluding 11 patients dying in-hospital and 2 erroneously included, the primary analysis comprised 386 patients (193 in each group) with median age 79 years (range 23-96) and number of diseases 7 (range 2-17).
interventionIntervention patients received pharmacist-led medicines management comprising medicines reconciliation at admission, repeated medicines reviews throughout the stay and medicines reconciliation and tailored information at discharge, according to the integrated medicines management model. Control patients received standard care. PRIMARY AND SECONDARY OUTCOME MEASURES: The primary endpoint was difference in time to readmission or death within 12 months. Overall survival was a priori the clinically most important secondary endpoint.
resultsPharmacist-led medicines management had no significant effect on the primary endpoint time to readmission or death within 12 months (median 116 vs 184 days, HR 0.82, 95% CI 0.64 to 1.04, p=0.106). A statistically significantly increased overall survival was observed during 21-40 months follow-up (HR 0.66, 95% CI 0.48 to 0.90, p=0.008).
conclusionsPharmacist-led medicines management had no statistically significant effect on time until readmission or death. A statistically significant increased overall survival was seen. Further studies should be conducted to investigate the effect of such an intervention on a larger scale. TRIAL REGISTRATION NUMBER: NCT02336113.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.